KarMMa-2
A Phase 2, Multi-Cohort, Copen-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma (KARMMA-2)
Filters
Save & Share
Clear Filters
Location
Explore options near your patient - or anywhere in the US.
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Near Add Your Location
Sort by
Herbert Irving Comprehensive Cancer Center (Columbia University)
Columbia University Medical Center
New York, NY
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
- Accepting patients
- Show Principal Investigator
127 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.